2024 AGM

March 6, 2024

Dear Shareholder:

We are pleased to invite you to our 2024 annual shareholder meeting to be held on April 23, 2024, via Event Conferencing.  We strongly recommend that you vote by proxy (pursuant to the instructions contained in your proxy form) or attend our 2024 annual shareholder meeting on Tuesday, April 23, 2024, by way of joining our Event Conferencing session via the following number:   for Toronto residents (416) 764-8658 or toll-free at 1-888-886-7786.  You will be provided with an opportunity to vote on the proposals contained in the attached proxy circular at the event conferencing session.  The proxy materials are first being made available to our shareholders on or about March 6, 2024.  The meeting will begin promptly at 1:00 p.m. PT.

In order to facilitate clear communications, all participants will be placed in lecture mode and will have their microphones muted.  We welcome questions and encourage you to email any questions that you may have regarding the proposals to the Company in advance of the meeting.  Please provide your questions to our Head of Legal, Vanessa Carle at vcarle@lexariabioscience.com as we will only have time to answer questions on proposals that are submitted in advance and a maximum of two (2) questions per proposal during the Meeting.  When we come to each proposal that requires a vote, we will have the moderator provide instructions on the process for asking questions for the purposes of discussion on the proposal.  Once the questions have been responded to, the moderator will provide instructions on the method of voting on the proposal.

In addition to the matters described in the Notice of Annual Meeting of Shareholders and the Proxy Statement, we will be conducting a question and answer session after the termination of the meeting (the “Q & A Session”) regarding Lexaria’s strategic business plan and the status of its research study programs, all as initially outlined in the Company’s annual letter issued on January 24, 2024 and available at https://ir.lexariabioscience.com/news-events/press-releases/detail/236/lexaria-releases-annual-letter-from-the-ceoThe Q & A Session will entail the Chief Executive Officer answering questions that were submitted in advance of the Meeting; it should be noted that no new questions will be taken from attendees during the Q & A session.  We strongly desire the opportunity to address any questions that you might have, so in order to ensure that we are able to address as many general questions as possible, we encourage you to forward your questions in advance of the meeting by emailing our Head of Legal, Vanessa Carle at vcarle@lexariabioscience.com who will then ensure that they are answered at the end of the meeting. 

The members of the Board and management hope that you and your loved ones continue to stay healthy and safe.    


/s/ Christopher Bunka
Christopher Bunka
Chief Executive Officer & Chairman

2024 Annual General Meeting Documents

Download 2024 Proxy Statement

Download Form of Proxy PDF

Download Form of Notice

Listen to the Meeting